查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553654

雙相情感障礙市場規模、佔有率、趨勢分析報告：按類型、藥物類別、分銷管道、地區和細分市場預測，2024-2030 年

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

雙相情感障礙市場成長與趨勢

Grand View Research, Inc.的最新報告顯示，2024年至2030年，全球雙極性情感障礙市場預計將以2.7%的複合年成長率成長，到2030年將達到58.7億美元。

政府對提高雙相情感障礙認知的支持以及有助於準確檢測患者情緒和精神狀態的技術進步是推動該市場成長的一些因素。

雙相情感障礙盛行率的上升預計將在預測期內推動市場成長。政府措施也將支持市場成長。例如，國際雙相情感障礙基金會的社會安全意外保險（SSDI）或補充保障收入（SSI）是美國社會安全局為受雙相情感障礙影響的人們提供的計劃。

此外，智慧型手機、智慧型手錶和穿戴式裝置的技術進步透過有效捕捉生理、行為和環境資料來檢測患者情緒和精神狀態，從而提高了診斷率。線上自我管理工具還可以及時干預，從而提高該疾病的診斷和治療率。然而，該市場重磅藥物的專利到期可能會影響預測期內的市場動態。此外，預計雙相情感障礙的治療將面臨學名藥的激烈競爭。其他因素，例如與雙相情感障礙治療相關的副作用和雙相情感障礙的誤診，可能會限制預測期內的市場成長。

雙相情感障礙市場報告亮點

  • 由於雙極性情感障礙的盛行率不斷上升，情緒穩定劑細分市場將在 2023 年以 35.0% 的市場佔有率佔據主導地位。
  • 2023年，選擇性血清素再回收抑制劑細分市場佔25.0%的市佔率。選擇性血清素再回收抑制劑（SSRI）的功效和安全性推動了市場成長，可有效控制雙相情感障礙引起的憂鬱症狀。
  • 2023年，醫院藥局領域以49.8%的佔有率佔據市場主導地位。這一市場的成長是由於尋求心理健康診斷的患者數量不斷增加。
  • 2023年，北美佔據雙極性情感障礙市場39.4%的佔有率。這是由於雙相情感障礙病例數量不斷增加以及該地區重要醫療設施的存在。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章雙向情感障礙市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 雙極性情感障礙市場分析工具
    • 波特的分析
    • PESTEL分析

第 4 章 雙極性情感障礙市場：按類型估計和趨勢分析

  • 細分儀表板
  • 雙極性情感障礙市場：2023 年和 2030 年類型變化分析
  • 情緒穩定劑
  • 抗驚厥藥
  • 抗精神病藥
  • 抗憂鬱症
  • 抗焦慮藥
  • 其他

第5章雙極性情感障礙市場：依藥物類別估計與趨勢分析

  • 細分儀表板
  • 雙極性情感障礙市場：2023 年和 2030 年藥物類別變化分析
  • 選擇性血清素再回收抑制劑
  • 正腎上腺素再回收抑制劑
  • 三環抗憂鬱藥物
  • 單胺氧化酵素抑制劑
  • 苯二氮平類
  • BETA受體阻斷劑
  • 其他

第6章雙向情感障礙市場：按分銷管道的估計和趨勢分析

  • 細分儀表板
  • 雙極性情感障礙市場：2023 年和 2030 年分銷管道波動分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章躁鬱症市場：區域估計/趨勢分析

  • 2023 年和 2030 年按地區分類的雙相情感障礙市場佔有率，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Advanced Micro Devices
    • AstraZeneca
    • Eli Lilly and Company
    • GSK plc
    • Johnson &Johnson Services, Inc
    • Pfizer Inc.
    • AbbVie Inc.
    • Otsuka Holdings Co., Ltd.
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Sumitomo Pharma America, Inc
簡介目錄
Product Code: GVR-2-68038-033-0

Bipolar Disorder Market Growth & Trends:

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights:

  • The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.
  • The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.
  • The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.
  • North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Bipolar Disorder Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Bipolar Disorder Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Mood Stabilizer
    • 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Anticonvulsants
    • 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Antipsychotic Drugs
    • 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Antidepressant Drugs
    • 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Antianxiety Drugs
    • 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Selective Serotonin Reuptake Inhibitor
    • 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Serotonin Norepinephrine Reuptake Inhibitor
    • 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Tricyclic Antidepressant Drugs
    • 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Monoamine Oxidase Inhibitors
    • 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Benzodiazepines
    • 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Beta Blockers
    • 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Drugs Classes
    • 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Bipolar Disorder Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Advanced Micro Devices
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eli Lilly and Company
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AbbVie Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Otsuka Holdings Co., Ltd.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bristol-Myers Squibb Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Teva Pharmaceutical Industries Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Sumitomo Pharma America, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives